Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).
Roberta Rudà, Riccardo Soffietti(Azienda Ospedaliero Universitaria San Giovanni Battista), Mauro Arcicasa, Antonio Silvani, Andrea Pietro Sponghini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ivan Lolli(Gastroenterology Hospital "Saverio de Bellis"), Matteo Santoni(University of Macerata), Marina Faedi(Inserm), Simona Vallarelli, Maurizio Salvati, F. Imbesi, Giuseppe Lombardi(University of Pisa), Manuela Caroli, Andrea Pace(Tumori Foundation), Alessia Pellerino(University of Turin), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Marinelli(University of Naples Federico II), Silvia Scoccianti, M. Balducci(Agostino Gemelli University Polyclinic), Francesco Pasqualetti
Cited by 0
Related Papers
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k